We are developing an inhibitory nerve cell therapy for the treatment chronic focal epilepsy and other disorders of the nervous system. In order to develop a maximally safe and effective cellular therapeutic, it is paramount to establish a robust and consistent manufacturing process, and to understand the molecular and cellular composition of the product. Under this award, we have successfully developed a pipeline to investigate global gene expression signatures of the product candidate, with single-cell/nucleus resolution, before and after administration into preclinical models. This work has led to an improved understanding of product composition and fate, and will ultimately help accelerate cell therapies toward future clinical trials.
